NPM1-Mutated AML: Not All Treatments Are Equal

Published Date: 19 Aug 2026

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Read Full News

Latest News

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Todays Updates

‘Modest’ Differences in OAT Should Not Obscure Benefits

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Todays Updates

‘Modest’ Differences in OAT Should Not Obscure Benefits

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Latest News

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Women with breast cancer show interest in self-injecting their medication.

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Ropeginterferon alfa-2b is designed to provide durable disease control.

News All Time

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

Industry trials focus on single drugs, while publicly funded trials often look at broader cancer care. It’s a ‘complementary’ approach, but pharma enrolls over 90% of patients.

Ruxolitinib Reduces Acute GVHD in Transplant Patients

A phase 3 trial evaluates a low-dose ruxolitinib-based regimen for graft-vs-host disease prophylaxis among patients undergoing haploidentical hematopoietic stem-cell transplantation.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Recommended News For You

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

Routine breast cancer screening can bring better outcomes for patients

Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

Drug-chemo combo increases cancer treatment efficacy

The Boom in ADHD Coaching Has Few Rules

Recommended Articles For You

Quality of Life Optimization in Long-Term Cancer Survivorship 

Quality of Life Following Functional Restoration of Bone Marrow Reserve 

Advancing Cancer Trials: Integrating Master Protocols and Immunotherapy Guidelines 

Environmental Carcinogen Exposure Screening: Advances, Clinical Implications, and Guideline-Based Approaches 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

2.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

3.

Invest in generics as a lesson from the shortages of chemotherapy.

4.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

5.

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

1.

The Importance of Having a Quick and Effective Heparin Antidote 

2.

A Comprehensive Guide To Understanding Plasma Osmolality

3.

Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice

4.

A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia

5.

Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Navigating the Complexities of Ph Negative ALL - Part XI

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion

5.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot